PASC is interested to define the baseline fracture rate and bone mineral density loss in the HIV population, how this differs from fracture rate and BMD loss in the broader population with age, and how a specific intervention (scanning and medication) can improve bone loss outcomes. Ideally the main outcome measure should be fracture rate. In the absence of this information change in BMD as measured by a or Z-score is an acceptable surrogate marker for the risk of MTF. References Australian Institute of Health and Welfare 2008. A picture of osteoporosis in Australia. Arthritis Australian Institute of Health and Welfare trial. Use of health services for arthritis and osteoporosis. Arthritis series no. 14. Cat. no. PHE 130. Canberra: AIHW. Australian Institute of Health and Welfare 2010b. Medication use for arthritis and osteoporosis. Cat. no. PHE 121. Canberra: AIHW. Australian Institute of Health and Welfare 2011. A snapshot of osteoporosis in Australia 2011. Arthritis series no. 15. Cat. no. PHE 137. Canberra: AIHW. Australian Medicines Handbook (AMH), URL: [accessed March 2012] Bedimo R, Zhang S, Dreschler H, Tebas P, Mallouf N. Risk of osteoporotic fractures associated with cumulative exposure to tenofovir and other antiretroviral agents. In: Program and abstracts of the 13th International Workshop on Adverse Drug Reactions and Comorbidities (Rome). London: International Medical Press, 2011. Bolland MJ, et al Low Body Weight Mediates the relationship between HIV infection and Low Bone Mineral Density: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism 92 (12) 4522-4528 2007 Bolland MJ, Wang TKM, Grey A et al 2011. Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab 96:2721-2731. Brown TT et al. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a review. AIDS 2006:20(17):2165-74. Center JR, D, Nguyen TV & Eisman JA 2007. Risk of subsequent fracture after low-trauma fracture in men and women. Journal of American Medical Association 297:387–94.
PASC is interested to define the baseline fracture rate and bone mineral density loss in the HIV population, how this differs from fracture rate and BMD loss in the broader population with age, and how a specific intervention (scanning and medication) can improve bone loss outcomes. Ideally the main outcome measure should be fracture rate. In the absence of this information change in BMD as measured by a or Z-score is an acceptable surrogate marker for the risk of MTF. References Australian Institute of Health and Welfare 2008. A picture of osteoporosis in Australia. Arthritis Australian Institute of Health and Welfare Use of health services for arthritis and osteoporosis. Arthritis series no. 14. Cat. no. PHE 130. Canberra: AIHW. Australian Institute of Health and Welfare 2010b. Medication use for arthritis and osteoporosis. Cat. no. PHE 121. Canberra: AIHW. Australian Institute of Health and Welfare 2011. A snapshot of osteoporosis in Australia 2011. Arthritis series no. 15. Cat. no. PHE 137. Canberra: AIHW. Australian Medicines Handbook (AMH), URL: [accessed March 2012] Bedimo R, Zhang S, Dreschler H, Tebas P, Mallouf N. Risk of osteoporotic fractures associated with cumulative exposure to tenofovir and other antiretroviral agents. In: Program and abstracts of the 13th International Workshop on Adverse Drug Reactions and Comorbidities (Rome). London: International Medical Press, 2011. Bolland MJ, et al Low Body Weight Mediates the relationship between HIV infection and Low Bone Mineral Density: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism 92 (12) 4522-4528 2007 Bolland MJ, Wang TKM, Grey A et al 2011. Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab 96:2721-2731. Brown TT et al. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a review. AIDS 2006:20(17):2165-74. Center JR, D, Nguyen TV & Eisman JA 2007. Risk of subsequent fracture after low-trauma fracture in men and women. Journal of American Medical Association 297:387–94. trial.
App1317-FinalDAP-accessible.docx